Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) is a phase 2, interventional study registered as NCT07243938 by Tao Zhang, with a registry enrolment figure of 70 participants, started 2026-01-15 and due to reach its primary completion in 2028-07-30. Interventions recorded: short-course radiotherapy; Zanidatamab; Tisleizumab(BGB-A317); Capecitabine; Oxaliplatin; TME surgery; S-1; D2. Conditions listed: Locally Advanced Rectal Cancer (LARC); Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (mCRC); Neoadjuvant Therapy. Primary outcome: Complete Response Rate (CR Rate); Pathological Complete Response Rate (pCR Rate); Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: "* Clinical diagnosis of gastric cancer and colorectal cancer". No results are recorded here; the registry entry is the source.